Flupirtina

CRITICAL: Flupirtine was withdrawn from European markets in March 2018 due to severe hepatotoxicity concerns including liver failure. Use was restricted to maximum 2 weeks in 2013 but cases of serious liver injury persisted. Monitor liver function closely; discontinue immediately if symptoms of liver damage appear (jaundice, dark urine, severe abdominal pain). Contraindicated in patients with pre-existing liver disease, chronic alcoholism, or taking other hepatotoxic medications. Never approved in the United States.

Also known as: Pruf, W-2964, D-9998, Awegal, Efiret

Classification

Chemical: Medicine
Psychoactive: Depressant
Tag: Aminopyridine
Tag: Analgesic
Tag: Muscle Relaxant
Tag: Pharmaceutical
Tag: Triaminopyridine derivative
Tag: Withdrawn-medication

Effects

Pain Relief
Muscle Relaxation
Sedation
Fatigue
Motor Impairment
Dizziness
Drowsiness
Reduced Anxiety
Anxiety Suppression
Dulled Perception
Disinhibition

Routes of Administration

Oral

Dosage

Threshold: 50 mg
Light: 100-150 mg
Common: 200-300 mg
Strong: 400 mg
Heavy: 600 mg

Duration

Onset: 0.5-1 h
Comeup: 0.5-1 h
Peak: 1-2 h
Offset: 4-6 h
After Effects: 24 h

Harm Reduction

Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.

Sources

Substance data is aggregated from the following public harm-reduction and reference sources.

dose.wiki

Links

This static page is intended as a readable non-JS and prerender-friendly library export.

Get the full DrugsPRO experience

Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.

Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu